A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma
Publication in refereed journal


Times Cited
Web of Science25WOS source URL (as at 19/11/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractIntroduction: A randomized phase 2 study was designed to compare the combination of ficlatuzumab (AV-299), a humanized hepatocyte growth factor-neutralizing monoclonal antibody, plus gefitinib versus gefitinib monotherapy in a pulmonary adenocarcinoma population clinically enriched for EFGR tyrosine kinase inhibitor sensitizing mutations.
All Author(s) ListMok TSK, Geater SL, Su WC, Tan EH, Yang JCH, Chang GC, Han M, Komarnitsky P, Payumo F, Garrus JE, Close S, Park K
Journal nameJournal of Thoracic Oncology
Year2016
Month10
Day1
Volume Number11
Issue Number10
PublisherELSEVIER SCIENCE INC
Pages1736 - 1744
ISSN1556-0864
eISSN1556-1380
LanguagesEnglish-United Kingdom
KeywordsEGFR TKI; Ficlatuzumab; HGF; Lung cancer; VeriStrat
Web of Science Subject CategoriesOncology; Respiratory System

Last updated on 2020-20-11 at 02:04